Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02600585 · ClinicalTrials.gov registry record
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
A clinical trial, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- 254,648
- Enrollment target
NCT02600585: Completed study, sponsored by Protein Sciences Corporation.
NCT02600585 is a clinical trial that has completed, run by Protein Sciences Corporation. The registered enrollment target is 254,648 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02600585 has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- 254,648 participants
- Enrollment target
Study Summary
The primary objective of this study is to retrospectively characterize the safety of Flublok in adults 18 years of age and older, in comparison with egg-based trivalent or quadrivalent inactivated influenza vaccines (IIVs), using a methodological approach designed to query the database of electronic health records (EHR) maintained by Kaiser-Permanente, Northern California (KPNC), a large medical care organization (MCO).
Primary Outcome
Incidence of Serious and/or Medically-Attended Adverse events
Interventions
- BIOLOGICAL Inactivated Influenza Vaccine
- BIOLOGICAL Recombinant Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254,648 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-09 |
What the finished NCT02600585 record still lists
NCT02600585 is an observational study that tracks outcomes without assigning an intervention. Its 254,648 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Inactivated Influenza Vaccine is the first listed.
NCT02600585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02600585 about?
NCT02600585 is a clinical study titled "Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults". The primary objective of this study is to retrospectively characterize the safety of Flublok in adults 18 years of age and older, in comparison with egg-based trivalent or quadrivalent inactivated influenza vaccines (IIVs), using a methodological approach designed to query the database of electronic...
What is the current status of trial NCT02600585?
This trial is currently completed. The enrollment target is 254,648 participants. The study started on 2015-11. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02600585?
The interventions under investigation include: Inactivated Influenza Vaccine (BIOLOGICAL), Recombinant Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02600585?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia